Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BFRI, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aminolevulinic Acid Hydrochloride FDA approved May 2016 · Ameluz |
Actinic Keratosis | Phase 3 · NCT01966120 | Completed |
| Ameluz 10% Topical Gel | Actinic Keratoses | Phase 4 · NCT06745999 | Active not recruiting |
| BF-200 Gel Formulation | Basal Cell Carcinoma (BCC) | Phase 3 · NCT02144077 | Completed |
| Methyl-5-Aminolevulinate Hydrochloride Cream | Actinic Keratosis | Phase 3 · NCT02799069 | Completed |
| Methyl Aminolevulinate | Basal Cell Carcinoma (BCC) | Phase 3 · NCT02144077 | Completed |
| Topical aminolevulinate (10% ALA gel) | Actinic Keratosis | Phase 2 · NCT06027619 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BFRI holds $3.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.5M/quarter from operations, an estimated runway of 6.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BFRI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | Institution (13G, 5%+) | 15,924,598 | 88.72% | 2026-09-30 |
| AIGH Capital Management LLC | Institution (13F) | 1,496,583 | 8.34% | 2026-09-30 |
| Orin Hirschman | Institution (13G, 5%+) | 915,210 | 5.10% | 2025-12-31 |
| Renaissance Technologies, LLC | Institution (13F) | 660,781 | 3.68% | 2026-09-30 |
| Unternehmensberatung Aktiengesellschaft 10% owner |
Insider | 458,884 | 2.56% | 2025-09-16 |
| Beteiligungen Aktiengesellschaft VV 10% owner Includes shares also reported by Unternehmensberatung Aktiengesellschaft Delphi, counted once |
Insider | 458,884 | 2.56% | 2025-09-16 |
| Wilhelm Konrad Thomas Zours 10% owner Includes shares also reported by Unternehmensberatung Aktiengesellschaft Delphi, counted once |
Insider | 458,884 | 2.56% | 2025-09-16 |
| Balaton Aktiengesellschaft Deutsche 10% owner Includes shares also reported by Unternehmensberatung Aktiengesellschaft Delphi, counted once |
Insider | 458,884 | 2.56% | 2025-09-16 |
| de la Huerta Martinez Maria del Pilar Director, 10% owner |
Insider | 400,000 | 2.23% | 2025-09-16 |
| Biofrontera AG Director, 10% owner · +3,019 options Includes shares also reported by de la Huerta Martinez Maria del Pilar, counted once |
Insider | 400,000 | 2.23% | 2025-06-30 |
| Hermann Luebbert CEO & Chairman, Director · +602,711 options |
Insider | 352,711 | 1.97% | 2026-07-28 |
| Eugene Frederick Leffler Chief Financial Officer · +336,250 options |
Insider | 206,250 | 1.15% | 2026-07-28 |
Share count 17,949,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-28 filed 2026-07-29 |
Luebbert Hermann |
Option exercise (M) | 62,500 | – | – |
| 2026-07-28 filed 2026-07-29 |
Luebbert Hermann |
Option exercise (M) | 62,500 | – | 352,711 |
| 2026-07-28 filed 2026-07-29 |
Leffler Eugene Frederick |
Option exercise (M) | 31,250 | – | – |
| 2026-07-28 filed 2026-07-29 |
Leffler Eugene Frederick |
Option exercise (M) | 31,250 | – | 206,250 |
| 2026-03-05 filed 2026-03-06 |
Luebbert Hermann |
Option exercise (M) | 137,500 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-09-28 | Ameluz | sNDA | -22.9% | -4.2% | -14% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BFRI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →